Dynamic Liver Chip Based on Well-Coupled Microfluidics: An Accurate NASH Model for Drug Evaluation
Analytical Chemistry · 2024
DOI: 10.1021/acs.analchem.4c03234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2024. Verfasst von Mingyang Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Shanghai Science and Technology Development Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
The convenient liver model in vitro recapitulating the hepatic functions, metabolism, and even steatohepatitis to perform the accurate drug evaluation is still challenging because of the unattainable hominine physiological microenvironment in vitro. Here, the progressed stages of nonalcoholic steatohepatitis (NASH) disease were precisely modeled to accurately evaluate the performance of antilipemic based on the dynamic liver chip adopting the well-coupled microfluidics, which well recapitulated the normal and steatohepatitis of liver in vitro. In brief, the mild nutrient flow and sufficient oxygen supply for parenchymal liver cells could be well supplied through the endothelial cells layer that mimicked the real physiological barrier of endothelium, while the loading of drugs might be obtained by directly adding drug into the running nutrient flow to mimic the intravenously administrable. The progressed degree of steatohepatitis could be directly reflected by the amount of intramyocellular lipid content (IMLC) of the HepG2 cell hepatocyte layer in wells that were induced by different concentrations of free fatty acids (FFA). To prove the concept of the liver chip in drug evaluation, an accurate assessment of the performance of firsocostat, the acetyl-CoA carboxylase (ACC) inhibitor of hepatic mitochondria of hepatocytes, was carried out. The subtle time dependence of firsocostat treatment to different progressed stages of NASH was clearly figured out. Therefore, we prospect the liver chip that adopted well-coupled microfluidics could be an accurate and standard liver model in vitro to carry out the antilipemic evaluation and screening, which significantly enlightens the drug evaluation by liver on chip in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.
- School of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
- Department of Gynaecology and Obstetrics, Shuguang Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai 201203, China.
ORCID-Profile: Hulie Zeng
Förderung
- Shanghai Science and Technology Development Foundation
- National Natural Science Foundation of China
Zitieren
APA
Chang, M., Fu, A., Liu, B., Wang, Y., & Zeng, H. (2024). Dynamic Liver Chip Based on Well-Coupled Microfluidics: An Accurate NASH Model for Drug Evaluation. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c03234
Vancouver
Chang M, Fu A, Liu B, Wang Y, Zeng H. Dynamic Liver Chip Based on Well-Coupled Microfluidics: An Accurate NASH Model for Drug Evaluation. Analytical Chemistry. 2024. doi:10.1021/acs.analchem.4c03234
BibTeX
@article{Chang2024,
author = {Chang, Mingyang and Fu, Anchen and Liu, Bingqian and Wang, Yongxiang and Zeng, Hulie},
title = {Dynamic Liver Chip Based on Well-Coupled Microfluidics: An Accurate NASH Model for Drug Evaluation},
journal = {Analytical Chemistry},
year = {2024},
doi = {10.1021/acs.analchem.4c03234}
}
EUVIMED